Field Notes from the Founder: Hard-Won Lessons in High-Risk Payments

We build payment processing for the brands everyone else turns away. These are the lessons that actually matter once you have lived through the freezes, the terminations, and the slow grind of earning a durable rail. If you sell research-use-only peptides or run a telehealth brand, this is the playbook.

Getting banked in a vertical nobody wants to touch

The hardest part of selling research-use-only peptides or running a telehealth brand is not the product or the marketing. It is keeping a working payment rail. Most processors say yes, take your volume for a few weeks, then freeze it the moment a risk model flinches. The fix is not a louder pitch to the processor. It is building your business so a compliance review is boring.

Why good merchants get shut off

Almost every termination I see traces back to the same handful of causes: human-use claims on an RUO product, chargebacks creeping past threshold, products that were never disclosed in underwriting, or sitting on an aggregator that treats you as someone else's risk. None of those are about whether your business is legitimate. They are about whether your account is legible to the people who have to defend it. More on the specific triggers in Why Peptide Brands Get Shut Off.

Compliance is the moat, not the tax

Founders treat compliance like a cost center. In high-risk payments it is the entire moat. The brands that survive are the ones with a clean research-use-only frame, a 21-and-over age gate, honest merchant category coding, and a refund and support operation that kills disputes before they start. That posture is what lets a processor keep you when a competitor with sloppier pages gets cut. See the website compliance checklist and why RUO labeling is the foundation.

Building the rail: why a platform with history beats a gateway

A multi-year operating history on a Stripe Connect platform is worth more than any clever workaround. Durability comes from being a known, accountable platform, not a fly-by-night gateway that disappears with your reserve. That is the difference between a rail you can plan a business around and one that evaporates on a bad Tuesday. Detail in How Stripe Connect Powers Compliant Processing.

The peptide and telehealth wave

The demand side of research peptides and incretin (GLP-1) category telehealth is enormous and growing. The bottleneck is not customers. It is banking access. Whoever can compliantly process for these merchants holds them for years, because switching processors in a high-risk vertical is painful. That is the opportunity, and the responsibility, in equal measure.

Programmable payments and where settlement is going

Before this, we built programmable card-to-mint payment technology. That lineage matters: it points at where high-risk settlement is heading, including crypto and stablecoin rails that give merchants optionality when card rails get tight. More in Crypto and Stablecoin Settlement.

The short version

If you are building in peptides, telehealth, or any vertical the banks avoid, the pattern is simple to say and hard to live: keep the research-use-only frame clean, disclose everything in underwriting, kill chargebacks before they start, and build on a rail with a track record. Do that, and you stop losing weeks to frozen funds and start compounding.

If your peptide or telehealth brand needs a payment rail built to survive scrutiny, apply and get approved. We do compliance-first processing for exactly these verticals.